{"id":2780,"text":"Highly active antiretroviral therapy (HAART) has greatly improved health parameters of HIV infected individuals.","label":[[0,44,"Drug"],[87,99,"Pathology"]],"Comments":[]}
{"id":2781,"text":"However, there are several challenges associated with the chronic nature of HAART administration.","label":[[76,81,"Drug"]],"Comments":[]}
{"id":2782,"text":"For populations in health transition, dual use of medicinal plant extracts and conventional medicine poses a significant challenge.","label":[],"Comments":[]}
{"id":2783,"text":"There is need to evaluate interactions between commonly used medicinal plant extracts and antiretroviral drugs used against HIV\/AIDS.","label":[[90,110,"Drug"],[124,127,"Pathology"],[128,132,"Pathology"]],"Comments":[]}
{"id":2784,"text":"Efavirenz (EFV) and nevirapine (NVP) are the major components of HAART both metabolized by CYP2B6, an enzyme that can potentially be inhibited or induced by compounds found in medicinal plant extracts.","label":[[0,15,"Drug"],[20,36,"Drug"],[65,70,"Drug"],[91,97,"Target"]],"Comments":[]}
{"id":2785,"text":"The purpose of this study was to evaluate the effects of extracts of selected commonly used medicinal plants on CYP2B6 enzyme activity.","label":[[112,118,"Target"]],"Comments":[]}
{"id":2786,"text":"Recombinant human CYP2B6 was used to evaluate inhibition, allowing the assessment of herb-drug interactions (HDI) of medicinal plants Hyptis suaveolens, Myrothamnus flabellifolius, Launaea taraxacifolia, Boerhavia diffusa and Newbouldia laevis.","label":[[18,24,"Target"],[134,151,"Herb name"],[153,179,"Herb name"],[181,202,"Herb name"],[204,221,"Herb name"],[226,243,"Herb name"]],"Comments":[]}
{"id":2787,"text":"The potential of these medicinal extracts to cause HDI was ranked accordingly for reversible inhibition and also classified as potential time-dependent inhibitor (TDI) candidates.","label":[],"Comments":[]}
{"id":2788,"text":"The most potent inhibitor for CYP2B6 was Hyptis suaveolens extract (IC It has been shown unequivocally that antiretroviral therapy (ART) reduces HIV\/AIDS mortality and prolongs life.","label":[[30,36,"Target"],[41,58,"Herb name"],[59,66,"Extraction process"],[68,70,"Parameter"],[108,136,"Drug"],[145,148,"Pathology"],[149,153,"Pathology"]],"Comments":[]}
{"id":2789,"text":"However, attention has now shifted from reduction in mortality to improvement of the quality of life for people taking ART [1,2].","label":[[119,122,"Drug"]],"Comments":[]}
{"id":2790,"text":"Across the world, there are huge disparities in health systems, thus, HIV\/AIDS patients in different geographical regions receive different ART regimens mostly due to the different cost of the more than 30 antiretroviral (ARV) drugs approved by the US FDA.","label":[[70,73,"Pathology"],[74,78,"Pathology"],[140,143,"Drug"],[206,232,"Drug"]],"Comments":[]}
{"id":2791,"text":"In resource constrained settings, the most commonly used ARV drugs include nevirapine (NVP) and efavirenz (EFV) which form the backbone of highly active antiretroviral therapy (HAART) regimens; thus, quite a number of patients use these two drugs during treatment [3,4].","label":[[57,66,"Drug"],[75,91,"Drug"],[96,111,"Drug"],[139,183,"Drug"]],"Comments":[]}
{"id":2792,"text":"Africa is a continent with a high prevalence of HIV\/AIDS making up approximately 67% of the world’s population of HIV infected people [5].","label":[[48,51,"Pathology"],[52,56,"Pathology"],[114,126,"Pathology"]],"Comments":[]}
{"id":2793,"text":"Most ARV drugs used in Africa include EFV and NVP.","label":[[5,14,"Drug"],[38,41,"Drug"],[46,49,"Drug"]],"Comments":[]}
{"id":2794,"text":"EFV and NVP are non-nucleoside reverse transcriptase I (NNRTIs) inhibitors which act by inhibiting the reverse transcriptase enzyme.","label":[[0,3,"Drug"],[8,11,"Drug"],[16,74,"Drug"],[104,131,"Target"]],"Comments":[]}
{"id":2795,"text":"Both EFV and NVP are relatively affordable when compared to other ARV drugs [6]; hence, they are widely used in many African countries.","label":[[5,8,"Drug"],[13,16,"Drug"],[66,75,"Drug"],[117,124,"Ethnic group"]],"Comments":[]}
{"id":2796,"text":"EFV and NVP are substrates of the CYP2B6 enzyme [7,8] and plasma concentrations of these two ARVs are affected by changes in levels and activity of CYP2B6.","label":[[0,3,"Drug"],[8,11,"Drug"],[34,40,"Target"],[93,97,"Drug"],[148,154,"Target"]],"Comments":[]}
{"id":2797,"text":"CYP3A4 also metabolizes these two drugs but its contribution appears to be marginal [9].","label":[[0,6,"Target"]],"Comments":[]}
{"id":2798,"text":"EFV and NVP have been associated with a number of side effects including liver damage, nausea, vomiting, fever, diarrhoea, dyslipidemia and headache [10].","label":[[0,3,"Drug"],[8,11,"Drug"],[50,62,"Pathology"],[73,85,"Pathology"],[87,93,"Pathology"],[95,103,"Pathology"],[105,110,"Pathology"],[112,121,"Pathology"],[123,135,"Pathology"],[140,148,"Pathology"]],"Comments":[]}
{"id":2799,"text":"CYP2B6 enzyme metabolizes many commonly used drugs including bupropion, propofol and cyclophosphamide which should not be given together with EFV or NVP, to avoid drug-drug interactions.","label":[[0,6,"Target"],[61,70,"Drug"],[72,80,"Drug"],[85,101,"Drug"],[142,145,"Drug"],[149,152,"Drug"]],"Comments":[]}
{"id":2800,"text":"Among populations in health transition, especially those in resource-constrained countries, patients often make use of herbal medicinal plants in the management and treatment of several diseases in addition to use of conventional drugs [11].","label":[],"Comments":[]}
{"id":2801,"text":"HIV infection is an epidemic in resource constrained countries, particularly in sub-Sahara Africa; thus, it is inevitable that there is dual use of HAART and herbal medicinal plants.","label":[[0,13,"Pathology"],[148,153,"Drug"]],"Comments":[]}
{"id":2802,"text":"Herbal medicine is much cheaper and readily available in most settings.","label":[],"Comments":[]}
{"id":2803,"text":"There is substantial evidence supporting the potential of medicinal plants in combating diseases, especially in developing countries [12,13,14,15].","label":[],"Comments":[]}
{"id":2804,"text":"Although effective in the treatment of some diseases, the mechanisms of action for most herbal medicines remain largely unknown.","label":[],"Comments":[]}
{"id":2805,"text":"A wide range of compounds (including phytochemicals) have been extracted from some of these medicinal plants so it is not inconceivable to be able to predict possible effects of herbal medicines on enzymes, such as CYP2B6, that metabolize commonly used drugs including EFV and NVP [16,17,18].","label":[[215,221,"Target"],[269,272,"Drug"],[277,280,"Drug"]],"Comments":[]}
{"id":2806,"text":"Some patients take herbal medicines and conventional medicines at the same time in a bid to get better more quickly, potentiating risk of herb–drug interaction (HDI) [19].","label":[],"Comments":[]}
{"id":2807,"text":"In spite of the wide use of herbal medications among HIV\/AIDs patients taking EFV or NVP-based HAART, data on their pharmacokinetic and pharmacodynamics properties in humans remain lacking or scant [11,20].","label":[[53,56,"Pathology"],[57,61,"Pathology"],[78,81,"Drug"],[85,88,"Drug"],[95,100,"Drug"]],"Comments":[]}
{"id":2808,"text":"Clinically significant interaction of herbs with prescribed medications via drug metabolism may worsen the health condition of patients if not detected earlier during treatment.","label":[],"Comments":[]}
{"id":2809,"text":"Cytochrome P450 enzymes (CYP450) are responsible for the metabolism of nearly 75% of phase I-dependent metabolism of clinically used drugs [21].","label":[[0,32,"Target"]],"Comments":[]}
{"id":2810,"text":"Relative expression of CYP2B6 ranges from 2% to 10% of the total hepatic content [22,23,24] and contributes to a significant proportion of drug metabolism [25].","label":[[23,29,"Target"]],"Comments":[]}
{"id":2811,"text":"Genetic polymorphism in CYP2B6 have been implicated in variations in the activity of the enzyme in metabolizing xenobiotics [26].","label":[[24,30,"Target"]],"Comments":[]}
{"id":2812,"text":"Inhibition of CYP2B6 by any drug, conventional and\/or herbal, is likely to present in a similar manner as portrayed by polymorphisms that result in deficient enzyme activity.","label":[[14,20,"Target"]],"Comments":[]}
{"id":2813,"text":"Thus, when herbal medicines are co-administered with ARV drugs, the possibility of herb-ARV drug interaction might be clinically significant and may lead to significant morbidity and mortality.","label":[[53,62,"Drug"],[88,96,"Drug"]],"Comments":[]}
{"id":2814,"text":"The purpose of this study was to evaluate the inhibition of CYP2B6 enzyme activity by selected medicinal plant extracts used by HIV patients to treat HIV-associated opportunistic infections.","label":[[60,66,"Target"],[128,131,"Pathology"],[150,189,"Pathology"]],"Comments":[]}
{"id":2815,"text":"The medicinal plant extracts evaluated were extracted from Hyptis suaveolens, Boerhavia diffusa, Newbouldia laevis, Launaea taraxacifolia and Myrothamnus flabellifolius.","label":[[20,28,"Extraction process"],[59,76,"Herb name"],[78,95,"Herb name"],[97,114,"Herb name"],[116,137,"Herb name"],[142,168,"Herb name"]],"Comments":[]}
{"id":2816,"text":"This study provides us with an opportunity to understand the effects of five medicinal plants—Hyptis suaveolens, Boerhavia diffusa, Newbouldia laevis, Launaea taraxacifolia and Myrothamnus flabellifolius—on CYP2B6 activity.","label":[[94,111,"Herb name"],[113,130,"Herb name"],[132,149,"Herb name"],[151,172,"Herb name"],[177,203,"Herb name"],[207,213,"Target"]],"Comments":[]}
{"id":2817,"text":"Data presented here can help to increase awareness among current and future patients of the potential effects of dual use of conventional drugs that are metabolized xenobiotic metabolising enzymes such as CYP2B6 and the above herbal medicinal plants.","label":[[205,211,"Target"]],"Comments":[]}
{"id":2818,"text":"Our data shows that, indeed, for most of these herbal compounds, there is need for caution when co-administering them with other medications.","label":[],"Comments":[]}
{"id":2819,"text":"The potential of each medicinal plant extract to inhibit activity of recombinant human CYP2B6 is presented in Figure 1 and Table 1.","label":[[38,45,"Extraction process"],[87,93,"Target"]],"Comments":[]}
{"id":2820,"text":"Four of the medicinal plant extracts inhibited CYP2B6 activity in a concentration dependent manner.","label":[[28,36,"Extraction process"],[47,53,"Target"]],"Comments":[]}
{"id":2821,"text":"The potency of inhibition exhibited by the extracts was in the order of Hyptis suaveolens (HS) > Myrothamnus flabellifolius (MF) > Boerhavia diffusa (BD) > Launaea taraxacifolia (LT).","label":[[43,51,"Extraction process"],[72,94,"Herb name"],[97,128,"Herb name"],[131,153,"Herb name"],[156,182,"Herb name"]],"Comments":[]}
{"id":2822,"text":"Newbouldia laevis did not show any concentration dependent inhibitory effects.","label":[[0,17,"Herb name"]],"Comments":[]}
{"id":2823,"text":"IC The IC IC The % yield and concentration per dose was calculated as shown in Table 2.","label":[[0,2,"Parameter"],[7,9,"Parameter"],[10,12,"Parameter"]],"Comments":[]}
{"id":2824,"text":"Since the intestinal absorption and plasma concentrations of each test compound are not known, and with the knowledge that herbal extracts have different bioavailability [28], the estimated bioavailable concentration was calculated using the % yield to give the soluble extract available in the GI tract.","label":[[130,138,"Extraction process"],[154,169,"Parameter"],[190,216,"Parameter"],[262,277,"Extraction process"]],"Comments":[]}
{"id":2825,"text":"Calculation of herbal medicine concentration in the gut.","label":[],"Comments":[]}
{"id":2826,"text":"Note: GIT, Gastrointestinal tract, estimated bioavailable concentration = (% yield × putative GIT concentration)\/100.","label":[[45,71,"Parameter"]],"Comments":[]}
{"id":2827,"text":"Using this assumption, the putative GIT concentration was calculated as shown in Table 2 and Table 3.","label":[],"Comments":[]}
{"id":2828,"text":"The IC In vivo prediction of HDI from in vitro for CYP2B6.","label":[[4,6,"Parameter"],[7,14,"Study"],[38,46,"Study"],[51,57,"Target"]],"Comments":[]}
{"id":2829,"text":"Note: HDI, herb-drug interaction, inhibitor concentration = estimated bioavailable concentration (µg\/mL), * the likelihood of a clinically relevant interaction when four of these herbal extracts are taken is based on the assumption that the % yield serves as the bioavailable fraction which was used in estimating the bioavailable concentration in the gut and also if there is complete absorption.","label":[[34,57,"Parameter"],[70,96,"Parameter"],[186,194,"Extraction process"],[318,344,"Parameter"]],"Comments":[]}
{"id":2830,"text":"The IC A fold decrease in IC Time dependent inhibition (TDI) classification of medicinal plant extract incubation based on IC Extracts of Hyptis suaveolens (HS), Boerhavia diffusa (BD), Myrothamnus flabellifolius (MF) and Launaea taraxacifolia (LT) on recombinant CYP2B6.","label":[[4,6,"Parameter"],[95,102,"Extraction process"],[123,125,"Parameter"],[126,134,"Extraction process"],[138,160,"Herb name"],[162,184,"Herb name"],[186,217,"Herb name"],[222,248,"Herb name"],[264,270,"Target"]],"Comments":[]}
{"id":2831,"text":"The bars represent ratio of IC Specific concentrations of the plant extracts were pre-incubated with or without NADPH and the percentage residual activity was compared (Figure 3).","label":[[28,30,"Herb part"],[68,76,"Extraction process"],[112,117,"Target"]],"Comments":[]}
{"id":2832,"text":"Medicinal plant extracts that were pre-incubated with NADPH showed a reduction in the percentage activity of CYP2B6 compared to those without NADPH with a significant effect observed for the Launaea taraxacifolia extract indicating its time dependent inhibitory potency without the possibility of enzyme activity recovery.","label":[[16,24,"Extraction process"],[54,59,"Target"],[109,115,"Target"],[142,147,"Target"],[191,212,"Herb name"],[213,220,"Extraction process"]],"Comments":[]}
{"id":2833,"text":"Hyptis suaveolens (HS), Boerhavia diffusa (BD), Myrothamnus flabellifolius (MF) and Launaea taraxacifolia (LT) on recombinant CYP2B6 after pre-incubation with or without NADPH for 30 min.","label":[[0,22,"Herb name"],[24,46,"Herb name"],[48,79,"Herb name"],[84,110,"Herb name"],[126,132,"Target"],[170,175,"Target"],[176,186,"Duration"]],"Comments":[]}
{"id":2834,"text":"Percentage residual activities were plotted against respective fractions.","label":[],"Comments":[]}
{"id":2835,"text":"Two-tailed unpaired t-test was used to compare the percentage residual activity of each fraction with p < 0.05 considered significant.","label":[],"Comments":[]}
{"id":2836,"text":"Inhibitory effects of 50 µg\/mL of each extract after pre-incubation in the presence and absence of NADPH.","label":[[39,46,"Extraction process"],[99,104,"Target"]],"Comments":[]}
{"id":2837,"text":"** Significant p value.","label":[],"Comments":[]}
{"id":2838,"text":"The relative quantification of phenolic compounds after UPLC-MS was performed using XCMS data analysis software.","label":[[31,49,"Herb name"]],"Comments":[]}
{"id":2839,"text":"Table 4 shows the relative quantification of the phenolic compounds analyzed using MS detection expressed in mg·kg Quantification of compounds identified in herbal extracts using MS detection.","label":[[49,67,"Herb name"],[164,172,"Extraction process"]],"Comments":[]}
{"id":2840,"text":"Note: values are expressed as mg·kg Structures of the phenolic compounds identified and quantified from crude herbal extracts (1) Caffeic acid; (2) Catechin; (3) Chlorogenic acid; (4) Epicatechin; (5) p-Coumaric acid.","label":[[54,72,"Herb name"],[104,125,"Extraction process"],[130,142,"Herb name"],[148,156,"Herb name"],[162,178,"Herb name"],[184,195,"Herb name"],[201,216,"Herb name"]],"Comments":[]}
{"id":2841,"text":"The use of medicinal plants for therapeutic purpose is a globally known phenomenon.","label":[],"Comments":[]}
{"id":2842,"text":"When adverse effects are experienced or cure fails, like in the case of HIV infection and cancer, limited resources could be used to promote the use of herbal medicines.","label":[[5,20,"Pathology"],[72,85,"Pathology"],[90,96,"Pathology"]],"Comments":[]}
{"id":2843,"text":"Thus, studies such as this one, which seek to scientifically validate the safety of herbal medicines, are imperative.","label":[],"Comments":[]}
{"id":2844,"text":"Herbal medicine is being used for the treatment of a wide spectrum of disease conditions including cardiovascular and viral disease, cancer and diabetes [29].","label":[[99,131,"Pathology"],[133,139,"Pathology"],[144,152,"Pathology"]],"Comments":[]}
{"id":2845,"text":"There is increasing evidence to also show that there is concomitant use of herbal medicines with conventional medicines which leads to clinical complications resulting from herb–drug interactions [11,19,30].","label":[],"Comments":[]}
{"id":2846,"text":"Studies on the drug interaction potential of herbal medicines, especially those that have been in use for centuries, will help to create an awareness of the potential for complications [31,32].","label":[],"Comments":[]}
{"id":2847,"text":"It is also imperative that identification of the phytochemical constituents in these herbal medicines be performed to identify those likely to cause drug interactions.","label":[],"Comments":[]}
{"id":2848,"text":"The advantage of phytochemical profiling is that similar drug interacting constituents could be identified in other related herbs that are used for therapeutic purposes and that necessary mechanistic studies are performed on them.","label":[],"Comments":[]}
{"id":2849,"text":"Guidelines from the FDA relating to drug interaction and identification of compounds which interact with drug metabolizing enzymes and transporters is of high value since these compounds play a major role in affecting the pharmacokinetic and pharmacodynamics profiles of allopathic medications [33].","label":[],"Comments":[]}
{"id":2850,"text":"In this study, five herbal medicines commonly taken to treat and manage the effects of HIV\/AIDS or its comorbidities by patients were evaluated for their ability to modulate activity of CYP2B6 in vitro using recombinant human CYPs.","label":[[87,90,"Pathology"],[91,95,"Pathology"],[186,192,"Target"],[193,201,"Study"],[226,230,"Target"]],"Comments":[]}
{"id":2851,"text":"Crude extracts of the herbal medicines were used because since patients take these extracts in their crude from, it became important that the effect of the crude form is evaluated.","label":[[0,14,"Extraction process"],[83,111,"Extraction process"]],"Comments":[]}
{"id":2852,"text":"The method of extraction used for this study was also performed to mimic the indigenous mode of extraction using water.","label":[],"Comments":[]}
{"id":2853,"text":"The study showed that Launaea taraxacifolia Hyptis suaveolens, Boerhavia diffusa and Myrothamnus flabellifolius extracts caused a concentration-dependent inhibition in CYP2B6.","label":[[22,43,"Herb name"],[44,61,"Herb name"],[63,80,"Herb name"],[85,111,"Herb name"],[112,120,"Extraction process"],[168,174,"Target"]],"Comments":[]}
{"id":2854,"text":"The US FDA, EMA and pharmaceutical industries have published opinion documents and guidelines for the conduct of drug enzyme inhibition studies [34,35,36] which include reversible and time dependent inhibition profiles of new chemical entities (NCE).","label":[],"Comments":[]}
{"id":2855,"text":"A reversible inhibition profile was thus conducted for the herbal extracts.","label":[[66,74,"Extraction process"]],"Comments":[]}
{"id":2856,"text":"It was observed that Hyptis suaveolens, Myrothamnus flabellifolius, Launaea taraxacifolia and Boerhavia diffusa had a reversible inhibitory effect on the activity of CYP2B6.","label":[[21,38,"Herb name"],[40,66,"Herb name"],[68,89,"Herb name"],[94,111,"Herb name"],[166,172,"Target"]],"Comments":[]}
{"id":2857,"text":"Newbouldia laevis, however, did not show any significant inhibitory effects on the activity of CYP2B6 based on the concentration range assessed.","label":[[0,17,"Herb name"],[95,101,"Target"]],"Comments":[]}
{"id":2858,"text":"Based on the recommended dosage taken by patients, the GIT concentration was calculated and % yield used to estimate the bioavailable concentration (Table 2) and the possibility of causing HDI in vivo determined.","label":[[121,147,"Parameter"],[193,200,"Study"]],"Comments":[]}
{"id":2859,"text":"Here, a comparison was made between the amount of extract in the gut and the IC According to US FDA, EMA and pharmaceutical industries guidelines on the conduct of drug enzyme inhibition studies [34,36,38], NCE that show significant reversible inhibition should also be assessed for time dependent inhibitory (TDI) effects.","label":[[50,57,"Extraction process"],[77,79,"Parameter"]],"Comments":[]}
{"id":2860,"text":"The IC Launaea taraxacifolia has been used for centuries in West African countries such as Ghana and Nigeria as a vegetable and also for managing dyslipidemia and liver diseases [42] which are complications of HIV\/AIDS, its comorbidities [43,44,45,46] and HAART [10,47,48,49].","label":[[4,6,"Parameter"],[7,28,"Herb name"],[60,72,"Ethnic group"],[146,158,"Pathology"],[163,177,"Pathology"],[210,213,"Pathology"],[214,218,"Pathology"],[256,261,"Drug"]],"Comments":[]}
{"id":2861,"text":"Patients on HAART regimens containing EFV and NVP are likely to experience adverse drug effects from Launaea taraxacifolia when used together.","label":[[12,17,"Drug"],[38,41,"Drug"],[46,49,"Drug"],[75,95,"Pathology"],[101,122,"Herb name"]],"Comments":[]}
{"id":2862,"text":"In resource-limited settings, Launaea taraxacifolia is a commonly used vegetable; thus, herb–drug interactions are highly likely to be reported.","label":[[30,51,"Herb name"]],"Comments":[]}
{"id":2863,"text":"Although the study analyzed effects of the crude herbal extracts as taken by patients and did not evaluate the effects of the individual phytochemical constituents or fractions, UPLC-MS was used to quantify some phenolic compounds known for their therapeutic effects and some that have been implicated in CYP inhibition.","label":[[43,64,"Extraction process"],[212,230,"Herb name"],[305,308,"Target"]],"Comments":[]}
{"id":2864,"text":"Quantification of catechin, p-coumaric acid, caffeic acid, epicatechin and chlorogenic acid was performed with known standards and analyzed using XCMS data analysis software.","label":[[18,26,"Herb name"],[28,43,"Herb name"],[45,57,"Herb name"],[59,70,"Herb name"],[75,91,"Herb name"]],"Comments":[]}
{"id":2865,"text":"Extract from Launaea taraxacifolia showed high content of chlorogenic acid (1662.98 mg·kg Miconazole nitrate was purchased from Sigma-Aldrich (St. Louis, MO, USA).","label":[[0,7,"Extraction process"],[13,34,"Herb name"],[58,74,"Herb name"],[90,108,"Drug"]],"Comments":[]}
{"id":2866,"text":"Black costar 96 well plates were obtained from Thermo Fischer Scientific (Pittsburgh, PA, USA).","label":[],"Comments":[]}
{"id":2867,"text":"Vivid The following plants Hyptis suaveolens (UCC\/BS\/687), Boerhavia diffusa (UCC\/BS\/688), Newbouldia laevis (UCC\/BS\/689) and Launaea taraxacifolia (UCC\/BS\/690), Table 5, used in the study were obtained and authenticated by botanists from the University of Cape Coast and samples were kept in the herbarium in the department of Biological sciences with voucher numbers as indicated.","label":[[27,44,"Herb name"],[59,76,"Herb name"],[91,108,"Herb name"],[126,147,"Herb name"]],"Comments":[]}
{"id":2868,"text":"Myrothamnus flabellifolius, Table 5, was obtained from Zimbabwe and authenticated by a botanist.","label":[[0,26,"Herb name"]],"Comments":[]}
{"id":2869,"text":"Leaves of the plants were air dried and made into a powder using mortar and pestle.","label":[[0,6,"Herb part"]],"Comments":[]}
{"id":2870,"text":"Ethical approval was obtained from the University of Cape Town Human Research Ethics committee with number HREC REF: 826\/2014.","label":[],"Comments":[]}
{"id":2871,"text":"Herbal plants and their medicinal value.","label":[],"Comments":[]}
{"id":2872,"text":"A sample of 10 g of leaves from each plant was prepared in 100 mL of distilled water and heated for one hour at 60 °C to mimic the indigenous mode of extraction.","label":[[20,26,"Herb part"]],"Comments":[]}
{"id":2873,"text":"The material was allowed to extract for 72 h at room temperature during which supernatant was decanted every 24 h and the solid residue reconstituted in the same volume of purified water for the extraction process to be repeated.","label":[[36,44,"Duration"],[103,113,"Frequency"]],"Comments":[]}
{"id":2874,"text":"The supernatants were pooled and centrifuged (14,000× g, 10 min) and filtered using filter paper (8 µm, Whatman International LTD, Maidstone, UK).","label":[],"Comments":[]}
{"id":2875,"text":"The filtrates were freeze-dried using a Virtis sentry freeze dryer (the Virtis Company, NC, Gardiner, NY, USA) and the resulting powders were weighed.","label":[],"Comments":[]}
{"id":2876,"text":"The dried extracts were stored in an airtight container and stored at −20 °C until needed for use.","label":[[4,18,"Extraction process"]],"Comments":[]}
{"id":2877,"text":"The medicinal plant extracts were screened for inhibitory effects on CYP2B6 using a two point screening assay that used two concentrations of the extracts, 10 µg\/mL and 100 µg\/mL, respectively.","label":[[20,28,"Extraction process"],[69,75,"Target"],[146,154,"Extraction process"]],"Comments":[]}
{"id":2878,"text":"The assays were performed using the Vivid Determination of time-dependent inhibition (TDI) followed the same procedure as that of the IC In order to identify and quantify constituents in the medicinal plant extracts, chromatographic separation was performed on a Waters Acquity UPLC system (Waters Corporation, Milford, MA, USA) coupled to a PDA detector and Synapt G2 (ESI negative) following the procedure described by Farag and Wessjohann [55].","label":[[134,136,"Herb part"],[207,215,"Extraction process"]],"Comments":[]}
{"id":2879,"text":"Quantification of glycosylated derivatives of epicatechin, catechin, chlorogenic acid, caffeic acid and p-coumaric acid was calculated from calibration curves of epicatechin, catechin, chlorogenic acid, and caffeic acid and p-coumaric acid standards, respectively.","label":[[18,42,"Herb name"],[46,57,"Herb name"],[59,67,"Herb name"],[69,85,"Herb name"],[87,99,"Herb name"],[104,119,"Herb name"],[162,173,"Herb name"],[175,183,"Herb name"],[185,201,"Herb name"],[207,219,"Herb name"],[224,239,"Herb name"]],"Comments":[]}
{"id":2880,"text":"Calibration curves for each reference compound ranged from 0.1 to 100 µg\/mL.","label":[],"Comments":[]}
{"id":2881,"text":"The data generated was exported into an excel spreadsheet and the amount of metabolite formed at the various concentrations relative to the control (residual activity) was calculated using Equation (1)  The percentage residual activity was plotted against the log transformed concentrations of the medicinal plant extracts and the miconazole (positive CYP2B6 inhibitor).","label":[[314,322,"Extraction process"],[331,341,"Drug"],[352,358,"Target"]],"Comments":[]}
{"id":2882,"text":"A sigmoid curve was then fitted using non-linear regression analysis and the IC Y: remaining CYP2B6 activity (percentage of control), [I]: concentration of medicinal plant extract, H: Hill coefficient.","label":[[77,79,"Parameter"],[93,99,"Target"],[172,179,"Extraction process"]],"Comments":[]}
{"id":2883,"text":"The difference between the calculated IC The assumptions to risk rank the HDI potential of all extracts used in this study was done according to the method of Awortwe et al.","label":[[38,40,"Parameter"],[95,103,"Parameter"]],"Comments":[]}
{"id":2884,"text":"[57].","label":[],"Comments":[]}
{"id":2885,"text":"Percentage yield of each extract was calculated from amounts extracted from each herbal plant material.","label":[[25,32,"Extraction process"]],"Comments":[]}
{"id":2886,"text":"To predict the likelihood of medicinal plant extracts interacting with hepatic CYP2B6, two assumptions were made: firstly, that extracts were completely soluble in the human Gastro intestinal tract (GIT) fluid volume of 250 mL.","label":[[45,53,"Extraction process"],[79,85,"Target"],[128,136,"Extraction process"]],"Comments":[]}
{"id":2887,"text":"The commonly used dose of the various extracts was estimated to be 200–400 mg. Based on the recommended dose used in humans, an estimated concentration per dose in GIT depending on the % yield was calculated; Secondly, that adequate amount of each extract enters the hepatic portal vein to interact with CYP2B6, if the IC We have shown that some of the medicinal plant extracts that have been used traditionally to cure different diseases may need to be carefully considered in the era of HAART treatment, especially when considering regimens containing EFV and NVP because of the effects of these herbal treatments on CYP2B6, an enzyme that is necessary in the deposition of many therapeutically used drugs.","label":[[38,46,"Extraction process"],[67,77,"Amount"],[248,255,"Extraction process"],[304,310,"Target"],[319,321,"Parameter"],[369,377,"Extraction process"],[489,504,"Drug"],[554,557,"Drug"],[562,565,"Drug"],[619,625,"Target"]],"Comments":[]}
{"id":2888,"text":"Research reported in this publication was supported by the National Research Foundation (NRF) under an Indigenous Knowledge Systems (IKS) Research Grant to Collet Dandara.","label":[],"Comments":[]}
{"id":2889,"text":"The views and opinions expressed are not those of the NRF but of the authors of the material published.","label":[],"Comments":[]}
{"id":2890,"text":"Nicholas Ekow Thomford is funded by an NRF grant-holder linked bursary from the IKS research grant awarded to Collet Dandara.","label":[],"Comments":[]}
{"id":2891,"text":"Sample Availability: Not available.","label":[],"Comments":[]}
{"id":2892,"text":"Collet Dandara, Ambroise Wonkam, Nicholas Ekow Thomford, Michelle Skelton, Dee Blackhurst and Faustina Adu contributed to the design of the study.","label":[],"Comments":[]}
{"id":2893,"text":"All authors have materially participated in the manuscript preparation.","label":[],"Comments":[]}
{"id":2894,"text":"Nicholas Ekow Thomford and Charles Awortwe performed the laboratory and data analysis.","label":[],"Comments":[]}
{"id":2895,"text":"Collet Dandara and Nicholas Ekow Thomford wrote the draft manuscript and interpretation of data.","label":[],"Comments":[]}
{"id":2896,"text":"Denis Chopera, Kevin Dzobo, Ambroise Wonkam, Dee Blackhurst and Michelle Skelton commented.","label":[],"Comments":[]}
{"id":2897,"text":"All authors reviewed the final manuscript.","label":[],"Comments":[]}
{"id":2898,"text":"The authors declare no conflict of interest.","label":[],"Comments":[]}
